[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"overall-survival\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:overall-survival":29},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,6,0,[8,51,81,107,137,158],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":32,"overallStatus":38,"whyStopped":4,"lastUpdateSubmitDate":39,"lastUpdatePostDateStruct":40,"startDateStruct":43,"completionDateStruct":45,"leadSponsor":47,"locationsCount":50},"100634686","sintilimab-chidamide-and-azacitidine-for-untreated-stage-i-ii-extranodal-nkt-cell-lymphoma-100634686",false,"NCT07542912","Sintilimab, Chidamide, and Azacitidine for Untreated Stage I-II Extranodal NK\u002FT-Cell Lymphoma","A Single-Arm, Multicenter, Phase II Study of Sintilimab Combined With Chidamide and Azacitidine in Patients With Treatment-Naïve Stage I-II Extranodal Natural Killer\u002FT-Cell Lymphoma (SCENT-3)","SCENT-3","Inclusion Criteria:\n\n1. Willingness to participate in the clinical study.\n2. Age ≥ 18 years at the time of signing the Informed Consent Form (ICF).\n3. Newly diagnosed ENKTL confirmed by histopathology at the study center.\n4. Eastern Cooperative Oncology Group (ECOG) performance status of 0 to 2.\n5. At least one evaluable or measurable lesion\n6. Ann Arbor stage I-II disease.\n7. PINK-E score ≥ 1.\n8. Adequate organ and bone marrow function, with no severe hematopoietic dysfunction or abnormalities in cardiac, pulmonary, hepatic, renal, or thyroid function, and no immunodeficiency.\n\nExclusion Criteria:\n\n1. Aggressive natural killer cell leukemia.\n2. Presence of hemophagocytic syndrome.\n3. Primary central nervous system (CNS) lymphoma or secondary CNS involvement.\n4. Patients with a known history of human immunodeficiency virus (HIV) infection and\u002For acquired immunodeficiency syndrome (AIDS).\n5. Patients with active chronic hepatitis B or active hepatitis C.","ALL","18 Years",{"count":20,"type":21},30,"ESTIMATED","INTERVENTIONAL",[24],"NA","This is an open-label, single-arm, multi-center Phase II clinical trial evaluating the efficacy and safety of a novel sequential regimen as first-line therapy for treatment-naïve patients with Extranodal NK\u002FT-cell Lymphoma (ENKTL). The study consists of a Screening Phase, a Safety Lead-in Phase, and a Treatment Phase. During the Safety Lead-in Phase, 6 patients will be enrolled to receive a fixed dose of Sintilimab and Chidamide combined with Azacitidine to verify the dose (testing 100mg\u002Fd on days 1-3 versus days 1-5). Following the lead-in, all subjects will undergo a 2-cycle Immunotherapy Induction Phase with the SCA regimen (Sintilimab, Chidamide, and Azacitidine). Subsequently, treatment will be stratified based on response: patients achieving Complete Response (CR) or Partial Response (PR) will receive 4 additional cycles of SCA consolidation, while those with Stable Disease (SD) or Progressive Disease (PD) will switch to 4 cycles of P-GemOx chemotherapy. Upon completion of systemic therapy, all patients will undergo consolidative involved-field radiotherapy (≥50Gy).",[27,28,29,30,31],"Complete Remission Rate， CRR","Progression Free Survival","Overall Survival","Adverse Event","Duration of Response",[33,34,35,36,37],"Extranodal NK\u002FT-cell Lymphoma","First-line Therapy","Sintilimab","Chidamide","Azacitidine","NOT_YET_RECRUITING","2026-04-17",{"date":41,"type":42},"2026-04-21","ACTUAL",{"date":44,"type":21},"2026-06-01",{"date":46,"type":21},"2029-06-01",{"name":48,"class":49},"Sun Yat-sen University","OTHER",1,{"id":52,"slug":53,"hasResults":11,"nctId":54,"briefTitle":55,"officialTitle":55,"acronym":4,"eligibilityCriteria":56,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":57,"targetDuration":4,"studyType":59,"phases":4,"briefSummary":60,"conditions":61,"keywords":68,"overallStatus":71,"whyStopped":4,"lastUpdateSubmitDate":72,"lastUpdatePostDateStruct":73,"startDateStruct":75,"completionDateStruct":77,"leadSponsor":79,"locationsCount":50},"100441118","long-term-follow-up-of-subjects-treated-with-car-t-cells-100441118","NCT05024175","Long-term Follow-up of Subjects Treated With CAR T Cells","Inclusion Criteria:\n\nSubjects will be asked to participate leading up to the last DF\u002FHCC corresponding main study visit.\n\nSubjects meeting the following criteria are eligible for study participation:\n\n* Provision of voluntary written informed consent by subject\n* CAR T cells were administered in DF\u002FHCC IRB corresponding main study\n\nExclusion Criteria:\n\nSubjects meeting the following criterion are to be excluded from study participation:\n\n\\- Subject unable to comply with study requirements",{"count":58,"type":21},45,"OBSERVATIONAL","This is a single site, non-randomized, open-label, long-term safety and efficacy follow-up study for Phase 1 studies that evaluate the safety and efficacy of CAR T cells: NCT05660369 (DF\u002FHCC# 22-175) and NCT06026319 (DF\u002FHCC# 23-474).",[62,63,64,65,66,67,29],"Long Term Adverse Effects","CAR-T","Duty to Follow Up","Adult","Progression-Free Survival","Disease-Free Survival",[69,70],"Long-Term Follow-up to CAR-T Cells","Follow-up Studies","RECRUITING","2026-03-13",{"date":74,"type":42},"2026-03-16",{"date":76,"type":42},"2023-08-07",{"date":78,"type":21},"2039-08-01",{"name":80,"class":49},"Marcela V. Maus, M.D.,Ph.D.",{"id":82,"slug":83,"hasResults":11,"nctId":84,"briefTitle":85,"officialTitle":86,"acronym":87,"eligibilityCriteria":88,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":89,"targetDuration":90,"studyType":59,"phases":4,"briefSummary":91,"conditions":92,"keywords":95,"overallStatus":71,"whyStopped":4,"lastUpdateSubmitDate":97,"lastUpdatePostDateStruct":98,"startDateStruct":100,"completionDateStruct":102,"leadSponsor":104,"locationsCount":50},"100612781","efficacy-of-dose-adjusted-regimen-on-survival-in-frail-adults-with-acute-lymphoblastic-leukemia-100612781","NCT07258043","Efficacy of Dose-Adjusted Regimen on Survival in Frail Adults With Acute Lymphoblastic Leukemia","Efficacy on Progression Free Overall Survival of a Dose-Adjusted Regimen in Frail Adult Patients With Acute Lymphoblastic Leukemia","EPOCH","Inclusion Criteria:\n\n* Diagnosed with acute lymphoblastic leukemia (ALL) according to the World Health Organization (WHO) criteria\n* Older than 18 years old\n* ECOG Performance Status Scale \\>1 or the Karnofsky Performance Status (KPS) \\\u003C80%.\n* Comorbidities: diabetes mellitus, arterial hypertension, thrombotic events, endocrine disorders, or any condition that hinders the administration of full-dose chemotherapy.\n* Toxicity prior to a standard chemotherapy regimen.\n* Both genders\n* Over 18 years of age\n* No upper age limit\n* Signed informed consent\n\nExclusion Criteria:\n\n´- Patients refractory to induction treatment\n\n* Patients who have previously received a low-intensity regimen due to comorbidities\n* Biphenotypic leukemia\n* CNS involvement at diagnosis requiring radiotherapy\n* Patients whose survival is expected to be less than 48 hours due to leukemiarelated complications\n* Patients with a history of ischemic or hemorrhagic stroke or severe neurological deterioration\n* Pregnant patients",{"count":58,"type":21},"1 Year","Acute lymphoblastic leukemia (ALL) is characterized by the abnormal proliferation of immature precursor cells, disrupting normal hematopoiesis and causing severe anemia and thrombocytopenia due to genetic mutations. Conventional treatment with intensive chemotherapy is limited for elderly patients or those with comorbidities, adversely affecting their survival. In Mexico, alongside a higher incidence, treatment-related complications are more frequent, particularly with drugs such as asparaginase or anthracyclines, which limits therapeutic efficacy. The transition to infusion-based therapies promises to reduce these complications, improve treatment tolerance, and optimize clinical outcomes, marking a significant advancement in the management of this disease. Modifying treatment regimens toward infusion therapies has the potential to significantly reduce adverse complications, enhance treatment tolerance, and ultimately improve clinical outcomes for patients who cannot benefit from conventional intensive regimens. This approach not only aims to optimize treatment effectiveness but also to minimize associated risks, thus representing an important advancement in the management of acute lymphoblastic leukemia in clinical settings such as those in Mexico",[93,94,29],"Acute Lymphobkastic Leukemia","Leukemia",[96,87],"acute lymphoblastic leukemia","2025-11-26",{"date":99,"type":42},"2025-12-02",{"date":101,"type":42},"2025-07-23",{"date":103,"type":21},"2026-07-26",{"name":105,"class":106},"Hospital General de Mexico","OTHER_GOV",{"id":108,"slug":109,"hasResults":11,"nctId":110,"briefTitle":111,"officialTitle":112,"acronym":4,"eligibilityCriteria":113,"healthyVolunteers":11,"sex":17,"minAge":114,"maxAge":115,"enrollmentInfo":116,"targetDuration":4,"studyType":22,"phases":118,"briefSummary":119,"conditions":120,"keywords":126,"overallStatus":71,"whyStopped":4,"lastUpdateSubmitDate":128,"lastUpdatePostDateStruct":129,"startDateStruct":131,"completionDateStruct":133,"leadSponsor":135,"locationsCount":50},"100378566","intraoperative-blood-pressure-management-and-dexamethasone-in-lung-cancer-surgery-100378566","NCT04209218","Intraoperative Blood Pressure Management and Dexamethasone in Lung Cancer Surgery","Impact of Intraoperative Blood Pressure Management and Dexamethasone on Patient's Outcomes After Lung Cancer Surgery: A 2 × 2 Factorial Randomized Controlled Trial","Inclusion Criteria:\n\n* Aged \\>50 years but \\\u003C90 years.\n* Diagnosed as resectable primary non-small cell lung cancer (stage IA-IIIA) and scheduled for radical surgery with an expected duration of \\>2 hours.\n* Agree to participate in this study and sign the informed consent.\n\nExclusion Criteria:\n\n* Clinical examinations suggest non-resectable lung cancer or patients scheduled for a biopsy surgery.\n* Recurrent or metastatic lung cancer.\n* History of cancer or complicated with cancer in other organs.\n* Long-term exposure to glucocorticoids or other immunosuppressant(s) due to autoimmune disease or organ transplantation.\n* Uncontrolled hypertension (systolic blood pressure \\>180 mmHg or diastolic blood pressure \\>110 mmHg); or requirement of vasopressors to maintain blood pressure.\n* Persistent atrial fibrillation, or acute cardiovascular events (acute coronary syndrome, stroke, or congestive heart failure) within 3 months.\n* Severe hepatic dysfunction (Child-Pugh C) or renal failure (requirement of renal replacement therapy).\n* Any other circumstances considered unsuitable for study participation by attending physicians or investigators.","50 Years","90 Years",{"count":117,"type":21},1988,[24],"Surgery is the front-line therapy for non-small cell lung cancer (NSCLC) but postoperative complications remains high and patients' long-term outcome is still challenging. In addition to surgery, anesthetic management particularly intraoperative blood pressure management and use of dexamethasone may affect patients' early and long-term outcomes after surgery for NSCLC. This study aims to investigate the impact of intraoperative blood pressure management and dexamethasone administration on early and long-term outcomes in patients undergoing surgery for lung cancer.",[121,122,123,124,29,125],"Lung Cancer","Surgery","Blood Pressure Management","Dexamethasone","Postoperative Complications",[121,127,123,124,29,125],"Radical Resection","2025-07-29",{"date":130,"type":42},"2025-07-31",{"date":132,"type":42},"2020-04-07",{"date":134,"type":21},"2029-12",{"name":136,"class":49},"Peking University First Hospital",{"id":138,"slug":139,"hasResults":11,"nctId":140,"briefTitle":141,"officialTitle":142,"acronym":143,"eligibilityCriteria":144,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":145,"targetDuration":4,"studyType":59,"phases":4,"briefSummary":147,"conditions":148,"keywords":4,"overallStatus":71,"whyStopped":4,"lastUpdateSubmitDate":150,"lastUpdatePostDateStruct":151,"startDateStruct":153,"completionDateStruct":155,"leadSponsor":156,"locationsCount":50},"100551642","microwave-ablation-versus-liver-resection-for-intrahepatic-cholangiocarcinoma-100551642","NCT06462742","Microwave Ablation Versus Liver Resection for Intrahepatic Cholangiocarcinoma","Microwave Ablation Versus Liver Resection for Intrahepatic Cholangiocarcinoma Within Milan Criteria","MALRIC","Inclusion Criteria:\n\n1. pathologically diagnosed iCCA based on the WHO classifications;\n2. curative-intent liver resection or microwave ablation;\n3. tumor within Milan criteria, namely single tumor ≤5cm in maximum diameter; multiple tumors ≤3 in number and each ≤3cm; no evidence of major vascular\u002Fhilar invasion, extrahepatic\u002Flymphatic metastasis or other malignancies;\n4. age ≥18 years.\n\nExclusion Criteria:\n\nPatients not meeting any one of the inclusion criteria were excluded.",{"count":146,"type":21},1000,"Thermal ablation has been recommended by worldwide guidelines as first-line treatment for hepatocellular carcinoma (HCC), while evidence regarding its efficacy for primary intrahepatic cholangiocarcinoma (iCCA) is lacking. The goal of this observational study is to study the efficacy of ablation in treating iCCA by comparing its prognosis with surgery. The main questions it aims to answer are:\n\n* Whether microwave ablation could achieve similar efficacy with liver resection in treating iCCA\n* What is the risk factor for ablation or surgery in treating iCCA\n* What kind of iCCA patients could receive ablation as their first-line treatment In this real-world multicenter cohort study, we will collect data of iCCA patients from hospitals who underwent microwave ablation (MWA) or liver resection (LR) for tumors within Milan criteria. Survival will be compared between patients treated by MWA or LR.",[29,149],"Disease-free Survival","2024-07-24",{"date":152,"type":42},"2024-07-25",{"date":154,"type":42},"2009-01-01",{"date":46,"type":21},{"name":157,"class":49},"Chinese PLA General Hospital",{"id":159,"slug":160,"hasResults":11,"nctId":161,"briefTitle":162,"officialTitle":163,"acronym":4,"eligibilityCriteria":164,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":165,"enrollmentInfo":166,"targetDuration":4,"studyType":22,"phases":168,"briefSummary":169,"conditions":170,"keywords":4,"overallStatus":71,"whyStopped":4,"lastUpdateSubmitDate":175,"lastUpdatePostDateStruct":176,"startDateStruct":178,"completionDateStruct":180,"leadSponsor":182,"locationsCount":50},"100532645","a-novel-target-delineation-scheme-in-high-grade-glioma-patients-a-randomized-single-blind-clinical-trial-100532645","NCT06215495","A Novel Target Delineation Scheme in High-grade Glioma Patients: a Randomized Single-blind Clinical Trial","A Novel Target Delineation Scheme Based on RTOG(Radiation Therapy Oncology Group) and EORTC(European Organisation for Research and Treatment of Cancer) Guidelines Impact on Survival Time and Radiotherapy Complications in High-grade Glioma Patients: a Single-center Randomized Single-blind Clinical Trial","Inclusion Criteria:\n\n1. High-grade glioma (2021 WHO grade III or IV)\n2. Age between 18-65 years old, Karnofsky performance status (KPS) score ≥ 70\n3. result of pregnancy test being negative within 7 days before enrollment, only applicable to women with reproductive potential\n4. The patient voluntarily joined this study and signed an informed consent form\n5. Willing to return for follow-up\n6. Willing to provide tissue and blood samples for this research\n7. Surgical treatment was completed without any postoperative complications (such as consciousness disorders, hematomas, lung infection and cardiac insufficiency)\n8. Radiotherapy within 4-6 weeks after surgery\n9. No contraindications for taking temozolomide\n\nExclusion Criteria:\n\n1. Low-grade glioma(2021 WHO grade I or II)\n2. had or having other type of malignant cancers\n3. not having been performed gross total resection of tumor\n4. Severe active comorbidities, systemic diseases or other serious comorbidities that would render the patient unsuitable for participation in this study or seriously interfere with the appropriate evaluation of the safety and toxicity of the prescribed regimen in the judgment of the investigator, including but not limited to persistent or active infections, symptomatic congestive heart failure, unstable angina pectoris, arrhythmia, or mental illness；\n5. Baseline MRI indicates a previous or recent risk of cerebral hemorrhage or hernia;\n6. Pregnancy or lactation, or pregnancy or childbirth during the expected trial period(from pre-screening or screening visits until 120 days after the last trial treatment)\n7. Unable to perform brain magnetic resonance imaging;\n8. Allergic to CT contrast agent, unable to perform enhanced CT examination;\n9. Remote transfer;\n10. Medical contraindications for receiving radiation therapy, such as active systemic lupus or scleroderma","65 Years",{"count":167,"type":21},88,[24],"The main question it aims to answer are:\n\n1. whether the new target delineation scheme can improve Progression-free Survival\n2. whether it can reduce the incidence of radiation complications in high-grade glioma patients.\n\nParticipants in trial group will be performed radiotherapy of new target delineation method after the completion of the operation within 4-6 weeks., while participants in the control group be performed radiotherapy of EORTC(European organisation for research and treatment of cancer) target delineation method.Temozolomide 75 mg \u002F ( m² · d ) will be given to both groups of patients during radiotherapy. After radiotherapy, its dose changes to 150 \\~ 200 mg \u002F ( m² · d ) for 5 days and stopped for 23 days as a cycle. There are 6 cycles in total.",[171,172,173,174,29],"Radiation Toxicity","MRI Simulated Positioning","High Grade Glioma","Progression-free Survival","2024-03-12",{"date":177,"type":42},"2024-03-15",{"date":179,"type":42},"2024-02-18",{"date":181,"type":21},"2027-06-01",{"name":183,"class":49},"Zhujiang Hospital"]